We remain committed to our R&D efforts, which have significantly contributed to our latest product innovations. This strategic investment will allow us to maintain our competitive advantage.
— Management Team
03Detailed Report
0HOY.L
Boston Scientific Corporation
Period
Q3 2024
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 28, 2026
Swipe to view all report sections
Executive Summary
Boston Scientific Corporation reported strong financial performance for the third quarter of 2024, driven by continued demand for its medical devices, particularly in the MedSurg and Cardiovascular segments. Revenue reached $4.21 billion, reflecting a year-over-year increase of 19.34% and a sequential growth of 2.16%. However, net income declined by 7.14% year-over-year, indicating potential margin pressures. The company’s strategic investments in research and development remain robust, totaling $407 million, demonstrating commitment to innovation in the face of competitive pressures.
Management highlighted several pivotal initiatives aimed at enhancing operational efficiency and expanding product offerings. While the operating income saw a notable increase of 40.96% quarter-over-quarter, the overall net income performance raises concerns to address profitability sustainability moving forward. Investors should monitor the company's ability to convert revenue growth into bottom-line results as it navigates market dynamics.
The gross profit margin slightly improved to 68.8%, indicative of effective cost management processes in place despite some increases in operational costs. The company's focus on innovative product launches is expected to positively impact margins moving forward as scale efficiencies are realized.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
4.21B
19.34%
2.16%
Gross Profit
2.90B
19.96%
1.65%
Operating Income
733.00M
5.77%
40.96%
Net Income
468.00M
-7.14%
44.44%
EPS
0.32
-5.88%
45.45%
Key Financial Ratios
Gross Profit Margin
Excellent
62.90%
Gross profit margin is exceptional, indicating strong pricing power and operational efficiency
Operating Profit Margin
Good
16.00%
Operating margin is healthy and competitive within industry standards
Net Profit Margin
Good
11.10%
Net profit margin is healthy and competitive within industry standards
Return on Assets
Weak
1.23%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
2.26%
Return on equity suggests inefficient capital allocation
Current Ratio
Adequate
1.48
Current ratio meets minimum requirements but limited cushion
Debt to Equity
Moderate
0.53
Debt-to-equity indicates balanced capital structure with manageable debt
P/E Ratio
High Growth
65.35x
Very high P/E indicates aggressive growth expectations, higher risk
Price to Book
Premium
5.91x
Trading at premium to book value, reflects strong intangibles or growth
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.